Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals plc (JAZZ) reported that executive officer Robert Iannone, EVP, Global Head of R&D & CMO, exercised stock options and sold shares on August 27, 2026. He exercised derivative securities covering 57,500 Ordinary Shares at exercise prices of $113.10 and $137.12 per share, acquiring the same number of Ordinary Shares. On the same date, he sold an aggregate of 76,921 Ordinary Shares in multiple transactions at weighted average prices ranging from approximately $247.86 to $252.76 per share. The filing states these trades occurred automatically under a Rule 10b5-1 trading plan adopted on May 28, 2026.
Jazz Pharmaceuticals plc (JAZZ) completed a private offering of $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 through its wholly owned subsidiary Jazz Investments I Limited, including the full exercise of the $150.0 million option granted to initial purchasers. The notes are senior unsecured obligations, fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals, and were sold under Section 4(a)(2) and Rule 144A exemptions.
The notes mature on September 15, 2032 and bear interest payable semi-annually at 1.875%. The initial exchange rate is 2.8150 ordinary shares per $1,000 principal amount (exchange price about $355.24 per share), with standard adjustment features and certain exchange rate increases upon specified corporate events or redemptions. The issuer may redeem the notes in defined tax, price, and low-outstanding-amount scenarios, and holders have a fundamental change put right at 100% of principal plus accrued interest.
Jazz estimates net proceeds of approximately $1,226.4 million and expects to use them for general corporate purposes. Concurrent with pricing, the company repurchased about $225.0 million of ordinary shares at $249.29 per share using existing cash under its July 2024 repurchase program. The filing notes that, based on an initial maximum exchange rate of 4.0113 shares per $1,000 principal amount, up to 5,014,125 ordinary shares may initially be issuable upon exchange of the notes.
Jazz Pharmaceuticals plc (JAZZ) received a Rule 144 notice indicating that director Ted W. Love intends to sell up to 1,527 shares of Jazz common stock. The shares are held at E*TRADE Financial and are tied to restricted stock vesting dated 08/28/2026, with a proposed sale date of 08/31/2026 on NASDAQ.
Jazz Pharmaceuticals plc (JAZZ) is the issuer for a planned sale of common stock reported under Rule 144 by director Rick E. Winningham. The notice covers 3,507 shares of common stock held at E*TRADE Financial Corporation, with an aggregate market value of $857,602.00, and a proposed sale date of August 31, 2026 on NASDAQ. The securities to be sold arise from restricted stock vesting on August 28, 2026, received as compensation. The form is signed by Paz Dizon under power of attorney for Rick E. Winningham.
Jazz Pharmaceuticals plc (JAZZ) has a notice of proposed sale filed under Rule 144 for common stock held for the account of director Patrick Kennedy. The filing lists 3,507 shares of common stock, to be sold through E*TRADE Financial Corporation on NASDAQ in connection with restricted stock vesting on August 28, 2026, categorized as compensation. The Form 144 is signed by Paz Dizon under power of attorney for Patrick Kennedy on August 31, 2026.
Jazz Pharmaceuticals plc (JAZZ) is the issuer of common stock referenced in a notice of proposed sale filed for the account of Patrick G. Enright under Rule 144. The notice covers a proposed sale of 3,507 shares of JAZZ common stock held at E*TRADE Financial Corporation.
The securities relate to restricted stock vesting designated as compensation, with an aggregate market value stated as $857,602.00. The Form 144 identifies the proposed sale date as August 31, 2026, with the transaction to occur on NASDAQ.
Jazz Pharmaceuticals plc (JAZZ) is the issuer for which Norbert G. Riedel, identified as a director, has filed a notice of proposed sale of common stock under Rule 144. The notice covers 3,507 shares of common stock, to be sold through E*TRADE Financial Corporation on or after August 31, 2026, with an indicated aggregate market value of $857,602.00. The shares derive from restricted stock vesting dated August 28, 2026 and are described as acquired from the issuer as compensation.
Jazz Pharmaceuticals plc (JAZZ) received a Form 144 notice indicating that director Mark Douglas Smith may sell up to 3,507 shares of Jazz common stock through E*TRADE Financial Corporation. The securities information section lists an aggregate market value of $857,602.00 for these shares. The shares to be sold are tied to restricted stock vesting on 08/28/2026 and are shown as issued by the company as compensation. The filing also reports that during the prior three months, Smith sold 1,157 shares of common stock on 06/15/2026 for an aggregate sale price of $266,746.00.
Jazz Pharmaceuticals plc (JAZZ) director Mary Elizabeth Henderson filed a Form 144 indicating an intention to sell 3,852 shares of JAZZ common stock through E*TRADE Financial Corporation on NASDAQ. The shares are related to restricted stock vesting on 08/28/2026, with an estimated aggregate market value of $941,968.
Jazz Pharmaceuticals plc (JAZZ) received a notice under Rule 144 that director Laura Hamill may sell shares of the company’s common stock. The planned sale covers 3,507 common shares, which were acquired from the issuer through restricted stock vesting as compensation. E*TRADE Financial Corporation is listed as the broker.